Afqlir

Afqlir is a pharmaceutical product containing aflibercept, used primarily for intravitreal administration. It is designed to address specific eye conditions by targeting vascular endothelial growth factor (VEGF).

Afqlir is generally used for the treatment of certain eye conditions that involve abnormal blood vessel growth within the retina. This medication works by inhibiting VEGF, a protein that promotes the growth of new blood vessels. It is often prescribed for conditions such as wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.

Common effects of Afqlir may include temporary vision disturbances, eye redness, and discomfort at the injection site. Some users might experience floaters or increased eye pressure. These effects are typically mild and transient, but any persistent or severe symptoms should be discussed with a healthcare provider.

Afqlir should be handled with care and administered by a healthcare professional. It is important to follow all safety guidelines provided by the manufacturer and healthcare provider. Patients should inform their healthcare provider about any allergies or medical conditions before using this medication.

Afqlir may interact with other medications, particularly those that affect blood clotting or immune response. It is advisable to discuss all current medications with a healthcare provider before starting treatment with Afqlir. Additionally, patients should avoid activities that may increase the risk of eye injury during the treatment period.